You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.


Cancer Type: Hematologic, Leukemia - Acute Myeloid (AML), Myelodysplastic Syndrome (MDS), Myeloproliferative Neoplasms (MPNs)      Intent: Palliative
Regimen Category: Evidence-Informed
New Drug Funding Program
    Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
New Drug Funding Program
    Azacitidine - Acute Myeloid Leukemia (AML)

You might also be interested in